Big data in pharma - From garbage to gold

In our data-heavy age, data becomes a treasure, a currency, a
valuable good. This is true especially for the biotech and
pharmaceutical industries, where data can inform the development of
novel drugs. But should own biomedical data – and where should the
lines between privacy and patient benefit be drawn? In the new
episode of We’re doomed, we’re saved, Andreas Horchler and Louise
von Stechow discuss new strategies of data sharing and ownership in
biomedicine and pharma.